Amendment and Mail Process Complete

AB CHECK

AbCheck s.r.o.

Amendment and Mail Process Complete

Trademark Snap Shot Amendment & Mail Processing Stylesheet
(Table presents the data on Amendment & Mail Processing Complete)

OVERVIEW

SERIAL NUMBER 88073859 FILING DATE 08/10/2018
REG NUMBER 0000000 REG DATE N/A
REGISTER PRINCIPAL MARK TYPE TRADEMARK
INTL REG # N/A INTL REG DATE N/A
TM ATTORNEY AVENT, TEAGUE A
L.O. ASSIGNED N70-NOT FOUND

PUB INFORMATION

RUN DATE 01/17/2020
PUB DATE N/A
STATUS 661-RESPONSE AFTER NON-FINAL-ACTION-ENTERED
STATUS DATE 01/16/2020
LITERAL MARK ELEMENT AB CHECK

DATE ABANDONED N/A DATE CANCELLED N/A
SECTION 2F NO SECTION 2F IN PART NO
SECTION 8 NO SECTION 8 IN PART NO
SECTION 15 NO REPUB 12C N/A
RENEWAL FILED NO RENEWAL DATE N/A
DATE AMEND REG N/A


FILING BASIS

FILED BASIS CURRENT BASIS AMENDED BASIS
1 (a) NO 1 (a) NO 1 (a) NO
1 (b) YES 1 (b) YES 1 (b) NO
44D NO 44D NO 44D NO
44E NO 44E NO 44E NO
66A NO 66A NO

NO BASIS NO NO BASIS NO


MARK DATA

STANDARD CHARACTER MARK NO
LITERAL MARK ELEMENT AB CHECK
MARK DRAWING CODE 3-AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/LETTER(S)/NUMBER(S)
COLOR DRAWING FLAG NO

CURRENT OWNER INFORMATION

PARTY TYPE 10-ORIGINAL APPLICANT
NAME AbCheck s.r.o.
ADDRESS Vedeckotechnicky Park Plzen
Teslova 3
Plzen, 30100
ENTITY 16-LTD LIAB CO
CITIZENSHIP Czech Republic

GOODS AND SERVICES

INTERNATIONAL CLASS 001
          DESCRIPTION TEXT Chemicals, in particular biochemical preparations, reagents, laboratory reagents, binding molecules, peptide or antibody libraries or peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, nucleic acid sequences coding for these molecules, all for scientific and industrial purposes and research purposes, for use in molecular biology, in particular for the identification and characterisation of molecules, in particular proteins, enzymes and nucleic acids
INTERNATIONAL CLASS 005
          DESCRIPTION TEXT Pharmaceutical and veterinary preparations, in particular preparations containing or consisting of binding molecules, peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, pharmaceutical and veterinary preparations comprising or consisting of nucleic acid sequences coding for these molecules for treating infectious, inflammatory and tumorigenic diseases; preparations for therapeutic purposes, in particular human medicine purposes, diagnostic purposes, therapy or diagnosis of infectious, inflammatory and tumorigenic diseases
INTERNATIONAL CLASS 042
          DESCRIPTION TEXT Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis; scientific and technological services and research projects for the identification and characterisation of binding molecules, namely in the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation of chemical analyses; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely in the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely in the field of antibody discovery, antibody research and antibody optimization, namely, scientific research in the field of antibodies; scientific and technological services and research projects in relation to antibody discovery, namely in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to screening of antibody libraries, namely in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors in the nature of research and development services in the field of antibodies; scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to antibody development strategies, namely scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely in the field of antibody research and drug design; scientific and technological services and research projects in relation to multi-factor antibody optimization, namely scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody technology, namely scientific research in the field of antibody research and antibody optimization

GOODS AND SERVICES CLASSIFICATION

INTERNATIONAL CLASS 001 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE
INTERNATIONAL CLASS 005 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE
INTERNATIONAL CLASS 042 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE

MISCELLANEOUS INFORMATION/STATEMENTS

CHANGE IN REGISTRATION NO
COLORS CLAIMED STATEMENT Color is not claimed as a feature of the mark.
DISCLAIMER W/PREDETER TXT "AB" OR "CHECK"
DESCRIPTION OF MARK The mark consists of letters "AB" and "CHECK" separated by an array of circles.

PROSECUTION HISTORY

DATE ENT CD ENT TYPE DESCRIPTION ENT NUM
01/16/2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED 016
01/15/2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE 015
01/15/2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED 014
07/17/2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED 013
07/17/2019 GNRT O NON-FINAL ACTION E-MAILED 012
07/17/2019 CNRT R NON-FINAL ACTION WRITTEN 011
06/13/2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED 010
06/13/2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE 009
06/13/2019 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED 008
01/02/2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED 007
01/02/2019 GNRT F NON-FINAL ACTION E-MAILED 006
01/02/2019 CNRT R NON-FINAL ACTION WRITTEN 005
11/28/2018 DOCK D ASSIGNED TO EXAMINER 004
08/21/2018 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED 003
08/18/2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM 002
08/14/2018 NWAP I NEW APPLICATION ENTERED IN TRAM 001

CURRENT CORRESPONDENCE INFORMATION

ATTORNEY Karen L. Elbing
CORRESPONDENCE ADDRESS Karen L. Elbing
CLARK+ELBING LLP
101 FEDERAL STREET, 15TH FLOOR
BOSTON MA 02110
DOMESTIC REPRESENTATIVE NONE

Amendment and Mail Process Complete [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed